The Q1 beat and $200M opt-out payment provide a strong financial base. Watch for rusfertide PDUFA in August 2026 and ICOTYDE commercial ramp. The stock may re-rate as revenue visibility improves.
PTGX drugs
PTGX drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 6 $103.97entry
- T+1 · 6mo ago −4.92%α −4.59% · $98.85
- T+5 · 6mo ago −3.87%α −5.00% · $99.95
- T+20 · 6mo ago −8.23%α −11.01% · $95.41
- T+60 · 4mo ago +31.42%α +29.36% · $136.64
Price Chart
How similar events traded
Executive Summary
Protagonist Therapeutics reported Q1 2026 revenue of $56.4M and GAAP EPS of $0.05, significantly exceeding consensus estimates of $16.3M and -$0.65. The beat was driven by a $50M milestone from ICOTYDE FDA approval and the rusfertide opt-out election triggering a $200M payment. The company turned profitable versus a year-ago loss, and cash runway extends through 2028, marking a major inflection point.
Key Financial Metrics
Key Facts
- Q1 2026 license and collaboration revenue $56.4M vs $28.3M YoY (99% increase)
- Net income $3.8M vs net loss $11.7M YoY; basic EPS $0.06 vs -$0.19
- ICOTYDE FDA approval triggered $50M milestone; rusfertide opt-out triggers $200M payment
- Cash and marketable securities $620M as of March 31, 2026, providing runway through at least 2028
Financial Impact
Q1 2026 revenue $56.4M (beat consensus $16.3M by 246%), GAAP diluted EPS $0.05 (beat consensus -$0.65 by 108%)
Risk Factors
- Revenue heavily reliant on non-recurring milestones and partner payments
- Rusfertide regulatory risk ahead of PDUFA (August 2026)
- Dependence on J&J (ICOTYDE) and Takeda (rusfertide) for commercialization
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-055629 |
| Document: tm2613550d1_8k.htm | 0001104659-26-055629 |
| Document: 0001104659-26-055629-index-headers.html | 0001104659-26-055629 |
| Document: 0001104659-26-055629-index.html | 0001104659-26-055629 |
| Document: 0001104659-26-055629.txt | 0001104659-26-055629 |
| 8-K Data (Synthetic) | 0001104659-26-055629 |
Track record
11 reports on PTGX
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $132.04 Now $124.83 −5.46% settles Feb 4
- Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $143.37 Now $124.83 −12.93% settles Feb 2
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $142.14 Now $124.83 −12.18% settles Jan 26
- Aug 10, 202614w ago 144 Bearish 5/10 Entry $148.29 to $143.37 Now $124.83 +15.82% ▲ +3.32% +2.83% vs SPY
- Jun 18, 202621w ago 8-K Neutral 3/10 Entry $115.03 to $143.40 Now $124.83 +8.52% ▲ +24.66% +22.92% vs SPY
- Jun 12, 202622w ago Institutional Cluster Mixed 5/10 Entry $109.78 to $145.94 Now $124.83 +13.71% ▲ +32.94% +29.67% vs SPY
- May 12, 202626w ago 144 Bearish 5/10 Entry $103.88 to $145.87 Now $124.83 −20.17% ▼ −40.42% −35.98% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 4/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 8, 202627w ago Insider Cluster Neutral 5/10 Entry $99.36 to $135.81 Now $124.83 +25.63% ▲ +36.68% +31.85% vs SPY
- May 5, 202627w ago 8-K Bullish 7/10 Viewing Entry $103.97 to $136.64 Now $124.83 +20.06% ▲ +31.42% +29.36% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers